Oxocrebanine inhibits proliferation of hepatoma HepG2 cells by inducing apoptosis and autophagy.
10.19540/j.cnki.cjcmm.20241101.403
- Author:
Zheng-Wen WANG
1
;
Cai-Yan PAN
1
;
Chang-Long WEI
1
;
Hui LIAO
1
;
Xiao-Po ZHANG
2
;
Cai-Yun ZHANG
3
;
Lei YU
4
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery/Hainan Clinical Medical Research Center for Liver Disease and Critical Liver Care, Hainan Cancer Hospital/Hainan Medical University Affiliated Cancer Hospital Haikou 570312, China.
2. School of Pharmacy, Hainan Medical University Haikou 570312, China.
3. Hainan Pharmaceutical Research and Development Science and Technology Park Haikou 570312, China.
4. College of Pharmacy/Drug Engineering Technology Research Center, Harbin University of Commerce Harbin 150076, China.
- Publication Type:Journal Article
- Keywords:
Stephania hainannensis;
apoptosis;
autophagy;
hepatic cancer cells;
oxocrebanine
- MeSH:
Humans;
Apoptosis/drug effects*;
Autophagy/drug effects*;
Cell Proliferation/drug effects*;
Hep G2 Cells;
Liver Neoplasms/genetics*;
Carcinoma, Hepatocellular/genetics*;
Caspase 3/genetics*
- From:
China Journal of Chinese Materia Medica
2025;50(6):1618-1625
- CountryChina
- Language:Chinese
-
Abstract:
The study investigated the specific mechanism by which oxocrebanine, the anti-hepatic cancer active ingredient in Stephania hainanensis, inhibits the proliferation of hepatic cancer cells. Firstly, methyl thiazolyl tetrazolium(MTT) assay, 5-bromodeoxyuridine(BrdU) labeling, and colony formation assay were employed to investigate whether oxocrebanine inhibited the proliferation of HepG2 and Hep3B2.1-7 cells. Propidium iodide(PI) staining was used to observe the oxocrebanine-induced apoptosis of HepG2 and Hep3B2.1-7 cells. Western blot was employed to verify whether apoptotic effector proteins, such as cleaved cysteinyl aspartate-specific protease 3(c-caspase-3), poly(ADP-ribose) polymerase 1(PARP1), B-cell lymphoma-2(Bcl-2), Bcl-2-associated X protein(Bax), Bcl-2 homologous killer(Bak), and myeloid cell leukemia-1(Mcl-1) were involved in apoptosis. Secondly, HepG2 cells were simultaneously treated with oxocrebanine and the autophagy inhibitor 3-methyladenine(3-MA), and the changes in the autophagy marker LC3 and autophagy-related proteins [eukaryotic translation initiation factor 4E-binding protein 1(4EBP1), phosphorylated 4EBP1(p-4EBP1), 70-kDa ribosomal protein S6 kinase(P70S6K), and phosphorylated P70S6K(p-P70S6K)] were determined. The results of MTT assay, BrdU labeling, and colony formation assay showed that oxocrebanine inhibited the proliferation of HepG2 and Hep3B2.1-7 cells in a dose-dependent manner. The results of flow cytometry suggested that the apoptosis rate of HepG2 and Hep3B2.1-7 cells increased after treatment with oxocrebanine. Western blot results showed that the protein levels of c-caspase-3, Bax, and Bak were up-regulated and those of PARP1, Bcl-2, and Mcl-1 were down-regulated in the HepG2 cells treated with oxocrebanine. The results indicated that oxocrebanine induced apoptosis, thereby inhibiting the proliferation of hepatic cancer cells. The inhibition of HepG2 cell proliferation by oxocrebanine may be related to the induction of protective autophagy in hepatocellular carcinoma cells. Oxocrebanine still promoted the conversion of LC3-Ⅰ to LC3-Ⅱ, reduced the phosphorylation levels of 4EBP1 and P70S6K, which can be reversed by the autophagy inhibitor 3-MA. It is prompted that oxocrebanine can inhibit the proliferation of hepatic cancer cells by inducing autophagy. In conclusion, oxocrebanine inhibits the proliferation of hepatic cancer cells by inducing apoptosis and autophagy.
